期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

OPG/RANKL/RANK系统在绝经后骨质疏松中的调节作用 被引量：9

Regulating function of OPG/RANKL/RANK system in postmenopausal osteoporosis
下载PDF
导出
摘要 绝经后骨质疏松(postmenopausal osteoporosis,PMOP)是危及老年妇女健康的一种常见病和多发病,而在近年在骨质疏松研究中发现的OPG/RANKL/RANK系统是解释骨质疏松形成机制的一个重大突破。本文对OPG/RANKL/RANK系统及其在雌激素参与下的调节作用作一综述。 Postmenopausal osteoporosis （PMOP） is a common and frequent disease that threatens the health of elder women. Researches in recent years reveal that OPG/RANKL/RANK system is a key breakthrough in explaining the mechanism of the development of osteoporosis. This paper reviews the regulating function of OPG/RANKL/RANK system together with estrogen.
作者 夏绍祥 陈亮
机构地区 苏州大学附属第一人民医院骨科
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2013年第1期74-78,共5页 Chinese Journal of Osteoporosis
关键词 绝经后骨质疏松 骨保护素 核因子ΚB受体活化因子配体 核因子ΚB受体活化因子 postmenopausal osteoporosis osteoprotegerin receptor activator of NF-κB ligand receptoractivator of NF-κB
分类号 R681 [医药卫生—骨科学]
  • 相关文献

参考文献34

  • 1Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2012 Aug;4 (4) :225-33.
  • 2Bucay N, Sarosi I, Dunstan CR,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 1 ;12(9) :1260-8.
  • 3Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000, 21 ; 192 (4) :463-74.
  • 4Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendrltic-cell function. Nature. 1997, 13; 390 (6656) :175-9.
  • 5Wong BR, Rho J, Arron J,et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N- terminal kinase in T cells. J Biol Chem. 1997, 3 ; 272 (40) : 25190-4.
  • 6Lacey DL, Timms E, Tan HL,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 17;93(2) :165-76.
  • 7Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a llgand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. ProcNatlAcad Sci U S A. 1998, 31 ;95(7) :3597- 602.
  • 8Kong YY,Yoshida H, Sarosi I,et al, Pennlnger JM. OPGL is a key regulator of osteoclastogenesis,lymphocyte development and lymph-node organogenesis. Nature. 1999, 28 ; 397 ( 6717 ) : 315- 23.
  • 9Ma R, Xu J, Dong B, et al. Inhibition of osteoelastogenesis by RNA interference targeting RANK. BMC Musculoskelet Disord. 2012, 22;13(1) :154.
  • 10Dougall WC, Glaccum M, Charrier K,et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 15 ;13(18) :2412-24.

二级参考文献10

  • 1Shi Wei,,Steven L Teiteibaum,et al.Receptor activator of nuclear factor-κB in osteoclast precursors[].The Journal of Endocrinology.2001
  • 2Lindberg MK,Erlandsson M,Alatalo SL,et al.Estrogen receptorαbut not estrogen re-ceptorβ,is involved in the regulation of the OPG/RANKL(osteoprotegerin/receptor activator of NF-κB ligand)ratio and serum interleukin-6in male mice[].The Journal of Endocrinology.2001
  • 3Locklin RM,Khosla S,Riggs BL.Mechanisms of biphasic arrabolic and catabolic effects of parathyroid hormone(PTH)on bone cells[].Bone.2001
  • 4Wuyts W,Wesenbeeck V,Morales-piga A,et al.Evaluation of the role of RANK and OPG genes in Paget‘s disease of bone[].Bone.2001
  • 5Menaa C,Reddy SV,Kurihara N.et al.Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget‘s disease of bone.[].The Journal of Clinical Investigation.2000
  • 6Lacey DL,Timms E,Tan HL,et al.Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation[].Cell.1998
  • 7Tomoyasu A,Goto M,Fujise N,et al.Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factors[].Biochemical and Biophysical Research Communications.1998
  • 8Darnay BG,Haridas V,Ni J,et al.Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase[].Journal of Biological Chemistry.1998
  • 9Wong B R,Josien R,Lee S Y,et al.The TRAF family of signal transducers mediates NF-kappa B activation by the TRANCE receptor[].Journal of Biological Chemistry.1998
  • 10Ikeda T,Kasai M,Utsuyama M,et al.Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus[].The Journal of Endocrinology.2001

共引文献19

同被引文献110

引证文献9

二级引证文献88

中国骨质疏松杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部